VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

400.95 EUR
-8.75 (-2.14%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to VX1. VX1 was compared to 75 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 has a decent growth rate and is not valued too expensively. This makes VX1 very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year VX1 was profitable.
  • In the past year VX1 had a positive cash flow from operations.
  • Of the past 5 years VX1 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: VX1 reported negative operating cash flow in multiple years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VX1's Return On Assets of 14.78% is amongst the best of the industry. VX1 outperforms 89.33% of its industry peers.
  • With an excellent Return On Equity value of 21.22%, VX1 belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
  • The Return On Invested Capital of VX1 (15.66%) is better than 93.33% of its industry peers.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 15.82%. This is above the industry average of 12.19%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • VX1's Profit Margin of 31.35% is amongst the best of the industry. VX1 outperforms 88.00% of its industry peers.
  • VX1's Profit Margin has declined in the last couple of years.
  • VX1's Operating Margin of 38.70% is amongst the best of the industry. VX1 outperforms 92.00% of its industry peers.
  • VX1's Operating Margin has declined in the last couple of years.
  • VX1 has a better Gross Margin (86.28%) than 76.00% of its industry peers.
  • VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VX1.DE Health Analysis

2.1 Basic Checks

  • VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
  • VX1 has less shares outstanding than it did 5 years ago.
  • VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.79
WACC8.73%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.36 indicates that VX1 has no problem at all paying its short term obligations.
  • The Current ratio of VX1 (2.36) is comparable to the rest of the industry.
  • VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of VX1 (2.00) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. VX1.DE Growth Analysis

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • The Earnings Per Share has been growing by 12.27% on average over the past years. This is quite good.
  • VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.90%.
  • VX1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.10% yearly.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • VX1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.80% yearly.
  • VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.17% yearly.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.30, which means the current valuation is very expensive for VX1.
  • VX1's Price/Earnings ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 80.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (26.69), we can say VX1 is valued inline with the index average.
  • The Price/Forward Earnings ratio is 22.85, which indicates a rather expensive current valuation of VX1.
  • Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 84.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.79, VX1 is valued at the same level.
Industry RankSector Rank
PE 25.3
Fwd PE 22.85
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than 80.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, VX1 is valued cheaper than 84.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 35.42
EV/EBITDA 23.62
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VX1 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.36
PEG (5Y)2.06
EPS Next 2Y11.49%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • VX1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (3/5/2026, 7:00:00 PM)

400.95

-8.75 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap101.73B
Revenue(TTM)12.00B
Net Income(TTM)3.68B
Analysts80
Price Target461.23 (15.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)6.21%
PT rev (3m)7.06%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)-0.46%
Valuation
Industry RankSector Rank
PE 25.3
Fwd PE 22.85
P/S 10.08
P/FCF 35.42
P/OCF 31.79
P/B 6.82
P/tB 7.48
EV/EBITDA 23.62
EPS(TTM)15.85
EY3.95%
EPS(NY)17.55
Fwd EY4.38%
FCF(TTM)11.32
FCFY2.82%
OCF(TTM)12.61
OCFY3.15%
SpS39.77
BVpS58.75
TBVpS53.6
PEG (NY)2.36
PEG (5Y)2.06
Graham Number144.75
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.12%
ROICexc(5y)40.76%
ROICexgc(3y)34.64%
ROICexgc(5y)58.61%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-38.98%
ROICexgc growth 5Y-26.28%
ROICexc growth 3Y-31.44%
ROICexc growth 5Y-19.05%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC8.73%
ROIC/WACC1.79
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%
EBIT growth 1Y5.79%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.86%
FCF growth 1Y346.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y541.25%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.74% in the next year.